Narcolepsy

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

See the latest developments in narcolepsy research.

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Explore effective strategies for managing narcolepsy, including personalized treatment plans, medication options, and lifestyle interventions for improved patient outcomes.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

In the phase 3 ENCORE trial, AXS-12 reduced the frequency of cataplexy attacks as compared with placebo at week 3 of the double-blind period.